Completion of Tender Offer

For immediate release 23 January 2015 

ABCAM PLC

("Abcam" or "the Company")

Completion of Tender Offer re acquisition of Firefly BioWorks Inc

Further to its announcement on 21 January 2015, Abcam plc (AIM: ABC), a global leader in the supply of life science research tools, today announces that it has it has completed the tender offer to purchase all outstanding Firefly BioWorks Inc ("Firefly") shares for cash [1].

The tender offer closed on 23 January 2015, at which time Abcam had received valid acceptances from shareholders holding 100 per cent. of Firefly's share capital.

 [1] This announcement, including any information included or incorporated by reference in this announcement, may contain forward-looking statements (including words such as "believe", "expect", "estimate", "intend", "anticipate" and words of similar meaning) which are based upon current expectations and assumptions regarding anticipated developments and other factors affecting the Abcam group. All statements other than statements of historical facts may be forward-looking statements and should not be treated as guarantees of future performance. These forward-looking statements involve risks and uncertainties, many of which are beyond the control of the Abcam group, and there are important factors that could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These forward-looking statements speak only as at the date of this announcement and accordingly undue reliance should not be placed on such statements.

For further information please contact:

Notes to Editors

About Firefly

Firefly offers a platform for solution-phase multiplexed detection of proteins and nucleic acids. The company's open platform allows industrial, academic, and clinical scientists to develop and use multiplexed biological assays on standard laboratory flow cytometers. Firefly was incorporated in 2009.

About Abcam

Abcam plc is a global leader in the supply of life science research tools, with a wide range of products and expert technical support, enabling scientists to analyse living cells at the molecular level and improving the understanding of health and disease.

Abcam is committed to providing scientists with an extensive choice of reagents and tools, with the most comprehensive, honest and up-to-date datasheets and customer reviews, fast delivery and helpful customer service & technical support. The Company's catalogue evolves with scientific research trends and is growing each year to provide customers with products to meet their research needs. The range now includes primary and secondary antibodies, proteins, peptides, lysates, biochemicals, immunoassays and other kits. Abcam also supports its customers by hosting a range of global scientific events, forums and webinars, providing opportunities for scientists to get together and present their work.

Headquartered in Cambridge, UK, Abcam has nine global subsidiary offices enabling local services and multi-language support and sells to over 100 countries. The Company was founded in 1998, and now employs over 750 people. Abcam was admitted to AIM in 2005 (AIM: ABC).

To find out more, please visit www.abcam.